Mabwell (Shanghai) Bioscience Co., Ltd.

{
  "main_header": {
    "sid": 1287544,
    "name": "Mabwell (Shanghai) Bioscience Co., Ltd.",
    "stock_name": "Mabwell (Shanghai) Bioscience Co., Ltd.",
    "full_name": "Mabwell (Shanghai) Bioscience Co., Ltd.",
    "name_url": "stocks-analysis/mabwell-shanghai-bioscience-co-",
    "exchange": 47,
    "exchangecode": "SHG",
    "country_id": 12,
    "currency": "CNY",
    "cmp": "37.07",
    "chg": 0.77,
    "chgp": "2.12%",
    "dir": 1,
    "prev_price": "36.30",
    "mcapval": "8,051.59",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "China Shanghai Composite",
    "isin": "CNE100005RD2",
    "curr_date": "Feb 11",
    "curr_time": "",
    "bse_nse_vol": "8.35 M",
    "exc_status": "Active",
    "traded_date": "Feb 11, 2026",
    "traded_date_str": "2026 02 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mabwell-shanghai-bioscience-co--1287544-47&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Mabwell (Shanghai) Bioscience Co., Ltd. Reports Strong Financial Performance in Q1 2025",
        "link": "https://www.marketsmojo.com/news/mojo-premium/mabwell-shanghai-bioscience-co-ltd-joins-momentum-now-strategy-for-strong-financial-growth-3790978",
        "imagepath": "",
        "date": "2026-01-13 15:36:00",
        "description": "<p><strong>Mabwell (Shanghai) Bioscience Co., Ltd.</strong>, a prominent player in the Pharmaceuticals & Biotechnology sector, has showcased a robust financial performance for the quarter ending March 2025. The company's net sales for the first nine months have reached CNY 122.8 MM, reflecting a significant growth rate of 19.94% compared to the previous year.</p>\n\n<p>In addition to impressive sales figures, <strong>Mabwell</strong> has reported a higher net profit for the half-year period, amounting to CNY -641.86 MM. This indicates a positive trend in the company's financial health, despite the challenges faced in the industry.</p>\n\n<p>Another noteworthy aspect of <strong>Mabwell</strong>'s financial results is the substantial decrease in raw material costs, which have fallen by 67.28% year-over-year. This reduction is expected to enhance the company's profitability and operational efficiency moving forwar..."
      }
    ],
    "total": 1,
    "sid": "1287544",
    "stock_news_url": "https://www.marketsmojo.com/news/mabwell-shanghai-bioscience-co--1287544"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Mabwell (Shanghai) Bioscience Co., Ltd. Reports Strong Financial Performance in Q1 2025

2026-01-13 15:36:00

Mabwell (Shanghai) Bioscience Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has showcased a robust financial performance for the quarter ending March 2025. The company's net sales for the first nine months have reached CNY 122.8 MM, reflecting a significant growth rate of 19.94% compared to the previous year.

In addition to impressive sales figures, Mabwell has reported a higher net profit for the half-year period, amounting to CNY -641.86 MM. This indicates a positive trend in the company's financial health, despite the challenges faced in the industry.

Another noteworthy aspect of Mabwell's financial results is the substantial decrease in raw material costs, which have fallen by 67.28% year-over-year. This reduction is expected to enhance the company's profitability and operational efficiency moving forwar...

Read full news article

View All News